<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Assessing Essentiality <span id='am-26' about='obo:NCBITaxon_5661' typeof='owl:Thing obo:NCBITaxon_38574 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_5658 obo:NCBITaxon_33682 obo:NCBITaxon_1286322 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_38568 obo:NCBITaxon_5653'><span id='am-27' property="rdfs:label" content="Leishmania donovani" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-30'  ></span><span id='am-31' property="oboInOwl:hasRelatedSynonym" content="Leishmania (Leishmania) donovani" datatype="xsd:string"></span>Leishmania donovani</span> Nitroreductase and <br /> Its Role Nitro Drug Activation <br /> Susan Wyllie, Stephen Patterson, Alan H. Fairlamb <br /> Division Biological Chemistry Drug Discovery, Wellcome Trust Biocentre, College Life Sciences, University Dundee, Dundee, Scotland, United <span id='am-51' about='obo:NCBITaxon_kingdom' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-52' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-53' property="rdfs:label" content="kingdom" datatype="xsd:string"></span>Kingdom</span> <br />  <br /> The nitroimidazole fexinidazole potential safe effective oral drug therapy treatment visceral leishmaniasis. <br /> To date, nitroheterocyclics used treatment leishmaniasis, relatively little known mecha- <br /> nism action. In African trypanosomes, nitro drugs reductively activated type I nitroreductase (NTR), absent mam- <br /> malian cells. Modulation nitroreductase levels <span id='am-14' about='obo:NCBITaxon_5690' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-15' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-16' property="rdfs:label" content="Trypanosoma" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-18'  ></span>Trypanosoma</span> brucei directly affected sensitivity nitro compounds, with <br /> reduced concentrations enzyme leading moderate nitro drug resistance. In view progression fexinidazole into <br /> clinical development visceral leishmaniasis, assess essentiality nitroreductase Leishmania donovani and <br /> the effect modulating nitroreductase levels susceptibility fexinidazole. The failure directly replace endogenous <br /> copies NTR gene, presence ectopic copy gene, suggests NTR gene essential the <br /> growth survival L. donovani promastigotes. Loss single chromosomal copy L. donovani NTR gene resulted in <br /> parasites mildly resistant (&lt;2-fold) predominant vivo metabolite fexinidazole, parasites overexpress- <br /> ing NTR 18-fold susceptible. These <span id='am-54' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-55'  ></span><span id='am-56' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-57' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-58' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>data</span> confirm Leishmania NTR plays pivotal role fexinidazole activation. <br /> Reliance single enzyme prodrug activation leave fexinidazole vulnerable emergence drug resistance. How- <br /> ever, essentiality NTR L. donovani promastigotes, combined limited resistance shown NTR single <br /> knockout cells, suggests potential spread NTR-based resistance fexinidazole limited. <br />  <br />  <br />  <br /> V    isceral leishmaniasis (VL), caused protozoan parasite <br />      Leishmania donovani, second largest parasitic killer after <br /> malaria, 200 million people currently risk from <br />                                                                                      zole successfully completed, phase II/III trials are <br />                                                                                      scheduled later year (7). Fexinidazole potential as <br />                                                                                      safe effective oral drug therapy treatment visceral <br /> infection. In 95% cases, death prevented timely                     leishmaniasis (8). Administration once-daily oral regimen of <br /> appropriate drug therapy (1); however, current treatment options                     200 mg fexinidazole kg body weight&#11002;1 5 days found <br /> are far ideal. In India, Bangladesh, Nepal, epicenter                   suppress infection mouse model visceral leishmaniasis by <br /> of VL infection, 60% world&#8217;s reported cases (2), con-                    98.4%, potency comparable seen current front- <br /> certed efforts eradicate disease 2015. At                   line antileishmanial miltefosine. In light findings, fexini- <br /> present, best available treatments anthroponotic VL                      dazole scheduled enter phase II clinical trials the <br /> miltefosine liposomal amphotericin B. Undoubtedly,                          treatment visceral leishmaniasis Sudan (Bernard P&#233;coul, <br /> drugs vastly superior previous therapies,                  DNDi, personal communication). <br /> limitations. The principal drawbacks miltefosine terato-                      Nitroheterocyclics used treatment of <br /> genicity, prolonged treatment regimen, high resistance po-                       leishmaniasis, result, relatively little known their <br /> tential (3). Problems associated amphotericin B include high                    mechanism action leishmania parasites. In African try- <br /> treatment costs, intravenous route administration, un-                     panosomes, mode action nifurtimox involves reductive <br /> responsiveness Sudanese VL patients (4). Thus, re-                     activation type I NADH-dependent nitroreductase (NTR), <br /> mains definite urgent need strengthen range treat-                   resulting generation cytotoxic, unsaturated open-chain <br /> ment options VL.                                                                 nitrile derivative (9). Overexpression leishmanial homolog <br />     In search more-effective treatments neglected dis-                   nitroreductase L. donovani increase sensi- <br /> eases, renewed chemotherapeutic                       tivity fexinidazole 15-fold sensitivity nifurtimox 19-fold <br /> potential nitroheterocyclic compounds. <span id='am-32' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-33'  ></span><span id='am-34' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-35' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>This</span> stems                        (8), indicating similar mechanisms involved L. <br /> largely success nifurtimox-eflornithine combination                      donovani African trypanosome, <span id='am-19' about='obo:NCBITaxon_5691' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_39700 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-20' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma brucei subgroup" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-23'  ></span><span id='am-24' property="rdfs:label" content="Trypanosoma brucei" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma (Trypanozoon) brucei" datatype="xsd:string"></span>Trypanosoma brucei</span>. Ge- <br /> therapy (NECT) treatment Gambian form human                        netic studies indicate nitroreductase essential sur- <br /> African trypanosomiasis (HAT) (5). Treatment NECT, con-                         vival African trypanosome vitro (10). However, modula- <br /> sisting oral nifurtimox 10 days eflornithine infusions <br /> for 7 days, resulted cure rates ca. 97%, leading its <br /> inclusion Essential Medicines List WHO (5). The                           Received 29 August 2012 Returned modification 11 October 2012 <br /> success nifurtimox NECT prompted Drugs                            Accepted 26 November 2012 <br /> Neglected Diseases Initiative (DNDi) undertake comprehen-                          Published ahead print 3 December 2012 <br /> sive screen 700 nitroheterocyclic compounds antiparasitic                        Address correspondence Susan Wyllie, s.wyllie@dundee.ac.uk. <br /> activity. As result, 2-substituted 5-nitroimidazole fexinida-                     Copyright &#169; 2013, American Society Microbiology. All Rights Reserved. <br /> zole (Hoe 239), shown antitrypanosomal activity al-                       doi:10.1128/AAC.01788-12 <br /> most 30 years ago (6), rediscovered. Subsequently, phase I                          The authors paid fee allow immediate free access article. <br /> clinical trials treating African sleeping sickness fexinida- <br />  <br />  <br /> February 2013 Volume 57 Number 2                                  Antimicrobial Agents Chemotherapy         p. 901&#8211;906                                 aac.asm.org   901 <br />  Wyllie et al. <br />  <br />  <br />  <br /> tion nitroreductase levels trypanosomatids             TABLE 1 Cloning primers <br /> shown directly affect sensitivity nitro compounds vitro,             Primer                    Primer sequencea <br /> with reduced enzyme activity leading moderate nitro drug re-               5=UTR-NotI_s          5=-ataagaatgcggccgcAGTCATGTGATGGTG <br /> sistance (10). In view progression fexinidazole clin-                                   GTTTACGGCA-3= <br /> ical development visceral leishmaniasis, clear po-         5=UTR-HindIII/PmeI_as 5=-gtttaaacttacggaccgtcaagcttTGTAGTTTCT <br /> tential nitroreductase-mediated drug resistance                                     CTTGCTGCTTTCC-3= <br /> addressed Leishmania spp. With mind, assess               3=UTR-PmeI/BamHI_s 5=-gacggtccgtaagtttaaacggatccTTTAGACTCG <br /> the essentiality nitroreductase Leishmania donovani                                      GCACCAGAGATGAGA-3= <br /> the effect modulation nitroreductase levels suscepti-            3=UTR-NotI_as         5=-ataagtaagcggccgcCCAAGACAGCAGCA <br /> bility nitro drugs.                                                                                 GCCGGTCGTGA-3= <br />                                                                               LdNTR-BamHI_s         5=-ggatccATGCTTCGCCGCAGTCGCCGCTT-3= <br />                                                                               LdNTR-BamHI_as        5=-ggatccTAGAACTTGTTCCACCGCACGGT-3= <br /> MATERIALS AND METHODS                                                         a <br />                                                                                 Capital letters represent nucleotides corresponding gene sequences L. infantum; <br /> Ethics statement. All animal experiments approved Ethical         lowercase letters represent additional sequences used generating constructs. <br /> Review Committee University Dundee performed un-           Restriction endonuclease sites underlined. <br /> der Animals (Scientific Procedures) Act 1986 (United Kingdom Home <br /> Office Project License PPL 60/4039) accordance European <br /> Communities Council Directive (86/609/EEC). <br />     Cell lines culture conditions. The clonal Leishmania donovani              The recovery vector generated amplifying LdBOB nitrore- <br /> cell line LdBOB (derived MHOM/SD/62/1S-CL2D) grown                ductase gene genomic DNA using LdNTR-BamHI sense and <br /> promastigotes 26&#176;C modified M199 medium, described previously        antisense primers. The PCR product cloned pCR-Blunt <br /> (11).                                                                         II-TOPO vector (Invitrogen) sequenced. The pCR-Blunt II- <br />     Test compounds. Fexinidazole sulfone synthesized described         TOPO-LdNTR construct digested BamHI, frag- <br /> previously (8). Compound purity determined liquid chromatog-           ment cloned pIR1SAT expression vector (14), resulting a <br /> raphy&#8211;mass spectrometry (LC-MS) &#11350;95%. The                 pIR1SAT-LdNTR construct. <br /> stocks nifurtimox used study provided Bayer, <span id='am-45' about='obo:NCBITaxon_260511' typeof='owl:Thing obo:NCBITaxon_33511 obo:NCBITaxon_186623 obo:NCBITaxon_41705 obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_7711 obo:NCBITaxon_1 obo:NCBITaxon_1489388 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_1489341 obo:NCBITaxon_33154 obo:NCBITaxon_7776 obo:NCBITaxon_170194 obo:NCBITaxon_134613 obo:NCBITaxon_7898 obo:NCBITaxon_32443 obo:NCBITaxon_41665 obo:NCBITaxon_2759 obo:NCBITaxon_6072'><span id='am-46'  ></span><span id='am-47' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="Argentina" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasRelatedSynonym" content="Argentina Linnaeus, 1758" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Argentina</span>,         Generation LdBOB transgenic cell lines. Mid-log-phase L. don- <br /> as kind gift. Nitrofurazone miltefosine purchased Sigma-      ovani promastigotes (LdBOB) transfected knockout or <br /> Aldrich Ltd.                                                                  recovery constructs using Human T-Cell Nucleofector kit the <br />     In vitro drug sensitivity assays. To examine effects test com-     Amaxa Nucleofector electroporator (program V-033). Following trans- <br /> pounds growth, triplicate promastigote cultures seeded 1 &#11003;       fection, cells allowed grow 16 24 h modified M199 me- <br /> 105 parasites ml&#11002;1. Parasites grown 5-ml cultures presence     dium (11) 10% fetal calf serum prior appropriate drug selection <br /> of drug 72 h, 200-&#65533;?&#65533;l aliquots culture added    (100 &#65533;?&#65533;g nourseothricin ml&#11002;1, 50 &#65533;?&#65533;g hygromycin ml&#11002;1, 20 &#65533;?&#65533;g puro- <br /> to 96-well plates; 50 &#65533;?&#65533;M resazurin added well; fluores-       mycin ml&#11002;1). Cloned cell lines generated limiting dilution, main- <br /> cence (excitation wavelength, 528 nm; emission wavelength, 590 nm)        tained selective medium, removed drug selection one <br /> measured 4 h incubation (12). Data processed using    passage prior experiments. <br /> GRAFIT (version 5.0.4; <span id='am-71' about='obo:NCBITaxon_36283' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_9126 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_9183 obo:NCBITaxon_2759 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-72' property="rdfs:label" content="Erithacus" datatype="xsd:string"></span><span id='am-73'  ></span><span id='am-74' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Erithacus</span> Software) fitted 2-param-           Southern blot analyses transgenic L. donovani cell lines. The ORF <br /> eter equation, data corrected background fluorescence,      5= UTR LdBOB NTR amplified PCR (using primers <br /> to obtain effective concentration inhibiting growth 50% (EC50):        listed Table 1 cloning L. donovani NTR [LdNTR] knock- <br />                                     100                                       constructs) PCR DIG Probe Synthesis kit (Roche). The re- <br />  <br />                                       &#20873; &#20874; <br />                           y &#11005;                                                 sulting digoxigenin (DIG)-labeled products used probes. Samples <br />                                       &#20851;I&#20852;     m <br />                                                                               genomic DNA (5 &#65533;?&#65533;g) wild-type (WT) transgenic cell lines <br />                                 1 &#11001; <br />                                      EC50                                     digested appropriate restriction endonucleases, diges- <br /> In equation, [I] represents inhibitor concentration m     tion products separated 0.8% agarose gel trans- <br /> slope factor. The experiments repeated times,     ferred positively charged nylon membrane (Roche). The membrane <br /> data presented weighted means plus weighted standard devia-        hybridized overnight DIG Easy Hyb solution (Roche) 42&#176;C with <br /> tions (12).                                                                   DIG-labeled TRYS ORF 5= UTR probes (2 &#65533;?&#65533;l PCR product). <br />     Amastigote drug sensitivity assays. In-macrophage drug sensitivity        Following hybridization, membranes washed twice low-strin- <br /> assays carried described previously (8), using starch-elicited    gency conditions (25&#176;C, 5 min, SSC 0.1% sodium dodecyl sulfate <br /> peritoneal macrophages harvested BALB/c mice. Macrophages           [SDS]) twice high-stringency conditions (68&#176;C, 15 min, 0.5&#11003; <br /> infected metacyclic promastigotes ratio 10 promastigotes 1    SSC 0.1% SDS), 1&#11003; SSC comprises 150 mM sodium chloride <br /> macrophage.                                                                   50 mM sodium citrate (pH 7.0). Bound probe detected using <br />     Generation knockout, overexpression, recovery constructs.          DIG immunological detection kit (Roche) according manufac- <br /> The primers used generate constructs genetic manipulation         turer&#8217;s instructions. <br /> designed using <span id='am-1' about='obo:NCBITaxon_5671' typeof='owl:Thing obo:NCBITaxon_38574 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_5658 obo:NCBITaxon_33682 obo:NCBITaxon_1286322 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_38568 obo:NCBITaxon_5653'><span id='am-2' property="oboInOwl:hasRelatedSynonym" content="Leishmania donovani infantum" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-5' property="rdfs:label" content="Leishmania infantum" datatype="xsd:string"></span><span id='am-6' property="oboInOwl:hasRelatedSynonym" content="Leishmania (Leishmania) infantum" datatype="xsd:string"></span><span id='am-7'  ></span><span id='am-8' property="oboInOwl:hasAlternativeId" content="NCBITaxon:5662" datatype="xsd:string"></span>Leishmania infantum</span> nitroreductase (NTR) sequence               Northern blot analyses transgenic L. donovani cell lines. Total <br /> in GeneDB (LinJ.05.0660) template (Table 1). The accuracy         RNA isolated mid-log-phase L. donovani (LdBOB) promasti- <br /> constructs assembled verified sequencing. NTR gene replacement         gotes (1 &#11003;108) using RNeasy Plus kit (Qiagen). Northern blot <br /> cassettes generated amplifying region DNA encompassing       analysis RNA samples carried separating RNA (10 &#65533;?&#65533;g) a <br /> 5= untranslated region (5= UTR), open reading frame (ORF), 3= UTR         1% (wt/vol) agarose-formaldehyde gel transferring RNA a <br /> of LdBOB NTR genomic DNA primers 5=UTR-NotI_s                   positively charged nylon membrane (Roche). The membrane <span id='am-66' about='obo:NCBITaxon_37965' typeof='owl:Thing obo:NCBITaxon_12908 obo:NCBITaxon_1'><span id='am-67' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-68' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-69' property="rdfs:label" content="hybrid" datatype="xsd:string"></span><span id='am-70'  ></span>hybrid</span>- <br /> 3=UTR-NotI_as, using Pfu polymerase. This sequence used         ized overnight DIG Easy Hyb solution (Roche) 68&#176;C DIG- <br /> template amplification individual regions used assem-   labeled NTR RNA probe, generated NTR ORF using DIG <br /> bly replacement cassettes containing selectable drug resistance        Northern starter kit (Roche). Following hybridization, membranes were <br /> genes encoding puromycin N-acetyltransferase (PAC) hygromycin             washed, bound probe detected manner identical that <br /> phosphotransferase (HYG), constructed exactly described previously         described Southern blots. Levels NTR transcripts cell <br /> (13).                                                                         line directly compared densitometry using ImageJ program. <br />  <br />  <br /> 902 aac.asm.org                                                                                                           Antimicrobial Agents Chemotherapy <br />                                                                                                                 Essentiality Leishmania donovani Nitroreductase <br />  <br />  <br />  <br />  <br />                                                                                   FIG 2 Analysis NTR transcript levels Northern blotting. (A) RNA sam- <br />                                                                                   ples (10 &#65533;?&#65533;g) prepared WT (lane 1), SKO (lane 2), OE (lane 3) <br />                                                                                   promastigotes analyzed Northern blotting. Blots hybridized <br />                                                                                   RNA probe generated LdBOB NTR gene. (B) Ethidium bro- <br />                                                                                   mide staining RNA samples loaded agarose-formaldehyde gel prior to <br />                                                                                   transfer. <br />  <br />  <br />  <br />  <br />                                                                                   replacing second copy PAC. This ectopic copy NTR <br />                                                                                   inserted ribosomal DNA (rDNA) locus SKO <br />                                                                                   cell line using pIR1SAT vector, encodes a <br /> FIG 1 Genotypic analysis WT, SKO, rDKO cell lines. (A) Southern blot       nourseothricin resistance gene (SAT), resulting constitutive <br /> analysis SalI-digested genomic DNA (&#11011;5 &#65533;?&#65533;g) wild-type L. donovani          expression NTR. All clones rDKO promastigotes con- <br /> (LdBOB) cells (lane 1), NTR single knockout (HYG) cells (lane 2), NTR single      firmed Southern blotting lost copies en- <br /> knockout (HYG) cells constitutively expressing NTR (lane 3), NTR double           dogenous NTR genes (Fig. 1A). Our failure directly replace both <br /> knockout (PAC HYG) cells constitutively expressing NTR (lane 4), and <br />                                                                                   endogenous copies NTR, presence ecto- <br /> &#8220;false&#65533;? NTR double knockout (PAC HYG) cells (lanes 5 7). The NTR <br /> ORF probe shows allelic LdNTR 6.5 kb, ectopic copy LdNTR &#11011;9 kb,      pic copy gene, strongly suggests NTR gene essen- <br /> and chromosomally rearranged copy NTR 5.5 kb (*). (B) Southern blot       tial successful growth survival L. donovani promas- <br /> analysis NotI-digested genomic DNA (&#11011;5 &#65533;?&#65533;g) wild-type L. donovani          tigotes culture. <br /> (LdBOB) cells (lane 1) NTR single knockout (HYG) cells (lane 2) probed            Modulation NTR levels L. donovani alters sensitivity to <br /> with 5= UTR NTR. (C) Structure NTR locus NTR single knock- <br /> out (HYG) cells. Black bars represent 5= UTR region upstream open      nitro drugs. Modulation nitroreductase levels Trypano- <br /> reading frame NTR, used probe Southern blot analysis.        soma brucei <span id='am-9' about='obo:NCBITaxon_5693' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_47570 obo:NCBITaxon_5653'><span id='am-10' property="rdfs:label" content="Trypanosoma cruzi" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-12'  ></span><span id='am-13' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Trypanosoma cruzi</span> shown directly <br /> NotI sites expected fragment sizes shown. The endogenous NTR gene        affect sensitivity nitro compounds vitro, reduced con- <br /> contains NotI site results 2-kb band. Successful replacement   centrations enzyme leading nitro drug resistance (10). To <br /> allelic copy endogenous gene HYG, does contain NotI <br /> site, results 9-kb fragment. <br />                                                                                   determine case L. donovani, sensi- <br />                                                                                   tivities WT, SKO, NTR-overexpressing (OE) promasti- <br />                                                                                   gotes number nitroheterocyclic compounds assessed. <br />                                                                                   First, modulation NTR transgenic cell lines con- <br /> RESULTS                                                                           firmed comparing NTR transcript levels Northern blotting <br /> Generation NTR-complemented null mutants. The essential-                       (Fig. 2). NTR transcript levels 1.7-fold lower SKO parasites <br /> ity L. donovani nitroreductase assessed classical gene                  4.2-fold higher OE parasites WT parasites, de- <br /> replacement, NTR sequentially replaced drug resis-                  termined densitometry. As expected, changes level of <br /> tance genes. The copy NTR gene replaced                 NTR cells correlated directly relative sensitivi- <br /> hygromycin resistance gene (HYG, encoding hygromycin <span id='am-76' about='obo:NCBITaxon_128483' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_216303 obo:NCBITaxon_37796 obo:NCBITaxon_1206795 obo:NCBITaxon_69555 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_6448 obo:NCBITaxon_2759 obo:NCBITaxon_6479 obo:NCBITaxon_216293 obo:NCBITaxon_6072'><span id='am-77'  ></span><span id='am-78' property="rdfs:label" content="Phos" datatype="xsd:string"></span><span id='am-79' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-80' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>phos</span>-                        ties nifurtimox nitrofurazone, nitrofuran compounds <br /> photransferase) homologous recombination subsequent                        known undergo NTR-catalyzed 2-<span id='am-40' about='obo:NCBITaxon_1118549' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_8936 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_57387 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-41'  ></span><span id='am-42' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-43' property="rdfs:label" content="Electron" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>electron</span> reduction try- <br /> selection hygromycin resistance, generating single knockout                 panosomes (Table 2). Promastigotes overexpressing NTR were <br /> (SKO) cell line (Fig. 1A B). SKO promastigotes grew                    16- 4-fold sensitive WT cells nifur- <br /> same rate culture homozygotes, cell density.                timox nitrofurazone, respectively. Conversely, SKO parasites <br /> Attempts create null mutant directly re-                   sensitive compounds, EC50s 7.2 2.5 <br /> placing second allelic copy puromycin N-acetyltrans-                 &#65533;?&#65533;M nifurtimox nitrofurazone, respectively, compared to <br /> ferase gene (PAC). On separate occasions, promastigotes re-                  values 5.0 1.4 &#65533;?&#65533;M WT cells. Similar NTR level-depen- <br /> sistant hygromycin puromycin recovered                      dent shifts sensitivity observed cells treated fexini- <br /> transfections. However, Southern blot analysis genomic DNA                     dazole sulfone, predominant active metabolite nitroim- <br /> from multiple clones putative double knockout (DKO)                      idazole fexinidazole vivo (8, 15). While parasites overexpressing <br /> cells revealed retained endogenous copy                  NTR 18-fold susceptible fexinidazole sulfone than <br /> NTR generated additional gene copy, presumably                    WT parasites, SKO promastigotes marginally sensitive <br /> by chromosomal rearrangement (Fig. 1A). Consequently, res-                      (&#65533;?2-fold [Table 2]). In contrast, concomitant shift in <br /> cued double knockout (rDKO) cell line generated intro-                     sensitivity promastigotes alkyl phospholipid milte- <br /> ducing ectopic copy NTR SKO promastigotes prior                     fosine. Thus, NTR plays crucial role activation fexini- <br />  <br />  <br /> February 2013 Volume 57 Number 2                                                                                                               aac.asm.org 903 <br />  Wyllie et al. <br />  <br />  <br />  <br /> TABLE 2 Sensitivities WT, SKO, OE promastigotes standard drugs experimental nitro compounds <br />                                                                                         EC50a (Hill slope) L. donovani <br /> Compound                                Structure                                       WT                                OE                              SKO <br />  <br />  <br /> Fexinidazole sulfone                                                                    7.2 &#11006; 0.2 (5.4)                   0.4 &#11006; 0.01b (2.3)               12.6 &#11006; 0.1b (2.3) <br />  <br />  <br />  <br /> Nifurtimox                                                                              5.0 &#11006; 0.05 (4.7)                  0.32 &#11006; 0.01b (2.8)              7.23 &#11006; 0.08b (2.5) <br />  <br />  <br />  <br /> Nitrofurazone                                                                           1.43 &#11006; 0.02 (5.5)                 0.35 &#11006; 0.01b (2.4)              2.5 &#11006; 0.02b (2.5) <br />  <br />  <br /> Miltefosine                                                                             7.7 &#11006; 0.1 (3.5)                   8.16 &#11006; 0.05 (3.8)               7.9 &#11006; 0.2 (3.3) <br />  <br /> a <br />     Expressed micromolar concentrations. Results weighted means standard errors independent experiments. <br /> b <br />     P, &#65533;?0.0001 comparison WT Student&#8217;s t test. <br />  <br />  <br />  <br /> dazole metabolites L. donovani, NTR depletion <br /> within cells lead minor levels resistance promastigotes. <br />     NTR modulation intracellular amastigotes. In manner <br /> identical seen insect-stage promastigotes, potency <br /> of fexinidazole sulfone intracellular mammalian-stage amasti- <br /> gotes materially altered changes cellular NTR levels. <br /> Metacyclic promastigotes (WT, SKO, OE) used infect <br /> starch-elicited mouse peritoneal macrophages, EC50s were <br /> determined cell line following 72-h incubation vary- <br /> ing concentrations drug (Fig. 3A). Intracellular amastigotes <br /> overexpressing NTR approximately 9-fold sensitive to <br /> fexinidazole sulfone (EC50, 0.7 &#65533;?&#65533;M) WT parasites (EC50, 6.4 <br /> &#65533;?&#65533;M), SKO parasites showed &#65533;?2-fold decrease sensitiv- <br /> ity drug (EC50, 8.8 &#65533;?&#65533;M). The finding loss single <br /> copy NTR gene leads fexinidazole resistance L. dono- <br /> vani keeping resistance mechanisms iden- <br /> tified laboratory-generated fexinidazole-resistant T. brucei cell <br /> lines (15). However, noted EC99 fexinida- <br /> zole sulfone intracellular SKO amastigotes (78.5 &#65533;?&#65533;M), cal- <br /> culated using Hill slopes, markedly different cal- <br /> culated WT amastigotes (69.6 &#65533;?&#65533;M). <br />     Loss allelic copy NTR did diminish infectivity <br /> of SKO metacyclic promastigotes: mean number amasti- <br /> gotes infected macrophage overall percentage in- <br /> fected macrophages untreated controls comparable to <br /> those seen WT-infected macrophage cultures (Fig. 3B C). <br /> However, parasites overexpressing NTR did appear lose <br /> &#8220;fitness.&#65533;? Both number OE amastigotes infected mac- <br /> rophage percentage macrophages infected OE                              FIG 3 Effects NTR modulation susceptibility fexinidazole sulfone. <br />                                                                                             The susceptibilities amastigotes cultured starch-elicited mouse peritoneal <br /> cell line significantly lower WT (P, 0.04                           macrophages determined. (A) The EC50s fexinidazole sulfone against <br /> and 0.03, respectively).                                                                    WT (open circles), SKO (HYG) (filled circles), OE (open squares) para- <br />                                                                                             sites determined. EC50s 6.4 &#11006; 0.9, 8.8 &#11006; 0.7, 0.7 &#11006; 0.06 &#65533;?&#65533;M were <br /> DISCUSSION                                                                                  fexinidazole sulfone WT, SKO, OE cell lines, respec- <br />                                                                                             tively. (B) The mean number WT, SKO, OE amastigotes infecting mouse <br /> Our inability knock allelic copies NTR,                        peritoneal macrophages untreated control cultures determined. Differ- <br /> presence ectopic copy gene, provides strong evidence                           ences number WT versus OE amastigotes infecting macrophages were <br /> that endogenous function NTR essential viability                          confirmed statistically significant (P &#11005; 0.04) using unpaired Student t <br /> of L. donovani promastigotes. This true African                             test (*). (C) The percentage macrophages infected WT, SKO, OE <br />                                                                                             amastigotes untreated control cultures determined. Differences the <br /> trypanosome: NTR deleted bloodstream-form                                 percentage macrophages infected WT versus OE amastigotes were <br /> T. brucei parasites (10). In case South American try-                            confirmed statistically significant (P &#11005; 0.03) using unpaired Student t <br /> panosome T. cruzi, NTR-null mutants epimastigote (insect                             test (*). All data means triplicate measurements. <br />  <br />  <br />  <br /> 904      aac.asm.org                                                                                                                   Antimicrobial Agents Chemotherapy <br />                                                                                                         Essentiality Leishmania donovani Nitroreductase <br />  <br />  <br />  <br /> stage) unable differentiate infectious metacyclic trypo-     tion, rationale likelihood developing resis- <br /> mastigotes infect mammalian cells (10). Thus, NTR             tance single agent relatively high, likelihood of <br /> activity appears absolute requirement virulence      developing resistance compounds significantly lower <br /> trypanosomatids mammalian hosts. The biological func-           (19). The use drug combinations circumvent resistance <br /> tions trypanosomal NTRs remain determined. However,             successful antimalarials (19), approach <br /> there evidence enzymes play role             seriously considered treatment visceral <br /> ubiquinone metabolism. Trypanosomal NTRs share fea-              leishmaniasis. Indeed, recent trial directly compared effi- <br /> tures mitochondrial NADH dehydrogenases (10), enzymes               cacies potential short-course combination treatments <br /> known catalyze transfer electrons NADH ubiqui-         standard monotherapy India (20). The re- <br /> none, leading generation ubiquinol (16). In addition,        sults study confirm combination treatments <br /> recent genomewide RNA interference (RNAi) target-sequencing              visceral leishmaniasis efficacious safe well <br /> screen T. brucei demonstrated link nitro drug action,       reduce emergence drug-resistant parasites. With pro- <br /> ubiquinone biosynthesis, nitroreductases (17). While         gression fexinidazole clinical development use <br /> studies required <span id='am-37' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-38' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-39' property="rdfs:label" content="order" datatype="xsd:string"></span>order</span> pinpoint precise essential      visceral leishmaniasis, work identify appropriate <br /> biological function trypanosomal NTRs, clear     partner drug nitroimidazole way. <br /> enzymes play crucial role activation nitro drugs. <br /> The essentiality enzymes &#8220;Tritryp&#65533;? parasites       ACKNOWLEDGMENTS <br /> also makes attractive targets development novel          This work supported grants (079838, 077705, 083481) to <br /> chemotherapeutic agents undergo reductive activa-            A.H.F. Wellcome Trust (http://www.wellcome.ac.uk). <br /> tion. <br />     Loss single chromosomal copy L. donovani NTR             REFERENCES <br /> gene resulted parasites mildly resistant ni-      1. Ritmeijer K, Davidson RN. 2003. Medecins Sans Fronti&#232;res interventions <br /> troheterocyclic compounds, including predominant vivo                 kala-azar Sudan, 1989 &#8211;2003. Trans. R. Soc. Trop. Med. Hyg. <br /> metabolite antileishmanial drug candidate fexinidazole.               97:609 &#8211; 613. <br /> These data, combined pronounced hypersensitivity dem-            2. Regional Technical Advisory Group Kala-azar Elimination. 2005. <br />                                                                              Report meeting, Manesar, Haryana, 20 &#8211;23 December 2004. <br /> onstrated promastigotes overexpressing NTR, confirm the <br />                                                                              WHO project IND CDR 714. SEA-VBC-88. World Health Organization <br /> Leishmania NTR plays pivotal role activation nitro               Regional Office South-East Asia, New Delhi, India. http://www.searo <br /> drugs general, mechanism action fexinidazole          .who.int/LinkFiles/Kala_azar_VBC-88.pdf. <br /> particular. Recent studies shown trypanosomal nitrore-          3. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. 2009. <br /> ductases catalyze sequential 2-electron reduction nifurti-            Developments treatment visceral leishmaniasis. Expert Opin. <br />                                                                              Emerg. Drugs 14:395&#8211; 410. <br /> mox, resulting generation cytotoxic, unsaturated open-        4. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, <br /> chain nitrile derivative (9). It remains seen                  Davidson R. 2007. Unresponsiveness AmBisome Sudanese <br /> fexinidazole metabolites undergo similar 2-electron re-            patients kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101:19 &#8211;24. <br /> duction catalyzed Leishmania nitroreductase. Importantly,          5. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, <br />                                                                              Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, <br /> these findings illustrate mechanism clinical resis- <br />                                                                              Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande <br /> tance fexinidazole emerge. Reliance single enzyme              V. 2009. Nifurtimox-eflornithine combination therapy second-stage <br /> for prodrug activation leave drugs fexinidazole vul-             African <span id='am-59' about='obo:NCBITaxon_31285' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_39700 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_5691 obo:NCBITaxon_5653'><span id='am-60' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma gambiense" datatype="xsd:string"></span><span id='am-61' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma (Trypanozoon) brucei gambiense" datatype="xsd:string"></span><span id='am-62' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-63' property="rdfs:label" content="Trypanosoma brucei gambiense" datatype="xsd:string"></span><span id='am-64'  ></span><span id='am-65' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Trypanosoma brucei gambiense</span> trypanosomiasis: multicentre, <br /> nerable emergence drug resistance. However, failure            randomised, phase III, non-inferiority trial. Lancet 374:56 &#8211; 64. <br /> to generate NTR-null promastigotes clearly suggests         6. Jennings FW, Urquhart GM. 1983. The use 2 substituted 5-nitro- <br />                                                                              imidazole, Fexinidazole (Hoe 239) treatment chronic T. brucei <br /> selective pressure Leishmania parasites retain NTR               infections mice. Z. Parasitenkd. 69:577&#8211;581. <br /> activity. This pressure added advantage limiting          7. Torreele E, Trunz BB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, <br /> the maximum levels fexinidazole resistance achievable,               Pecoul B. 2010. Fexinidazole&#8212;a new oral nitroimidazole drug candidate <br /> SKO promastigotes 2-fold resistant drug. In            entering clinical development treatment sleeping sickness. PLoS <br />                                                                              Negl. Trop. Dis. 4:e923. doi:10.1371/journal.pntd.0000923. <br /> recent studies T. cruzi, laboratory-generated benznidazole- <br />                                                                           8. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, <br /> resistant parasites lost single copy NTR         Read KD, Fairlamb AH. 2012. The anti-trypanosome drug fexinidazole <br /> gene, mutations arising remaining copy gene                shows potential treating visceral leishmaniasis. Sci. Transl. Med. <br /> abolished enzyme activity (18). However, &#8220;functional null&#65533;?             4:119re1. doi:10.1126/scitranslmed.3003326. <br /> parasites demonstrated reduced levels virulence          9. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation trypano- <br />                                                                              somal type I nitroreductases generates cytotoxic nitrile metabolites. J. <br /> capacity highly drug resistant T. cruzi parasites spread         Biol. Chem. 286:13088 &#8211;13095. <br /> within population severely compromised. At           <br /> </body></html>